Method development for analysis of gliclazide in human plasma by using high-performance liquid chromatography.
Since 1970, dissolution requirements have been included in tablets and capsules monographs, in general, in response to concerns for bioavailability of equal significance is the recognition of the immense value of dissolution testing as a tool for quality control. Thus, equivalence in dissolution behaviour was sought in the light of both bioavailability and quality control considerations (Coppack et al., 1990). Nonetheless, dissolution profiles are often considered by the industry to ascertain the release rates of drug from tablet formulations as a quality assurance tool. However, in terms of sensitivity, precision and specificity, high-performance liquid chromatographic (HPLC) method may offer additional advantages (Charles & Ravenscroft, 1984 and Nawaz, 2001).